/
Psychiatry
Major Depressive Disorder
68
Pipeline Programs↗
159
Active Trials↗
84
Companies Involved↗
Major Depressive Disorder is a moderately active landscape with 68 programs across 84 companies. The most active players are Vanda Pharmaceuticals, Definium Therapeutics US, Inc., Nanjing Chia-tai Tianqing Pharmaceutical. 18 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical36
Phase 212
Phase 318
Approved
No programs
Analysis
Modality Breakdown
98%
Small molecule
63 of 64 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 64 classified programs, each share of the total. Modality classified for 94% of 68 pipeline programs.
Analysis
Trial Status
734
clinical trials
Completed455 · 62%
Recruiting82 · 11%
Terminated52 · 7%
Not yet recruiting45 · 6%
Unknown status42 · 6%
Active, not recruiting24 · 3%
Other34 · 5%
Clinical Trials
Trial Activity
734 trials
Examining the Effects of Escitalopram and Memantine on Pattern Separation in Major Depressive Disorder
Recruiting·—·Phase 1·NCT07139834·30 enrolled
Page 1 of 49
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)